In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
[google_news title=”” keyword=”Inventing drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Inventing drugs
- Three Congressional Letters Show the March-In Debate Has Shiftedon February 26, 2024 at 12:15 pm
When the Biden Administration unleashed its proposed march-in guidelines last December, it claimed they would be a powerful tool for lowering drug prices by allowing the government to “march in” to ...
- City of Hope scientists devise novel strategy to seek and destroy leukemia stem cellson February 26, 2024 at 11:54 am
Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem ...
- Orchid Pharma Gets USFDA Nod, To Market Drug In US Soonon February 26, 2024 at 10:47 am
The company has received approval from the United States Food and Drug Administration (USFDA) for its invention Enmetaobactam, a Beta Lactamase Inhibitor. According to the company, the USFDA approval ...
- A Biden proposal to lower the cost of drugs threatens to upend Pennsylvania’s high-tech economy | Opinionon February 26, 2024 at 5:53 am
I am dismayed by the Biden administration’s attempt to disrupt this system and the decades-long consensus surrounding Bayh-Dole.
- Meet the District 9 candidates: ‘How would you reduce overdose deaths?’on February 26, 2024 at 2:39 am
Drug dealers don’t sell because they like selling drugs but ... Second, you remove the dealers because there is no profit for them. Don’t insist on re-inventing the wheel. Copy Switzerland and ...
- Feds Make a Pharma Patent Grabon February 25, 2024 at 3:01 am
Under the Bayh-Dole system, it's easier for inventions (including pharmaceuticals ... law in a way its creators explicitly stated it was not intended to be used. "When drug companies won't sell ...
- Congressional efforts to lower drug costs keep falling short. Here's whyon February 25, 2024 at 1:47 am
Bringing a generic drug to market typically requires only about $1 million and takes a year or two. By contrast, developing a biosimilar can take up to nine years and come at a cost of $300 million.
- Biden plays the price is righton February 23, 2024 at 8:09 am
President Joe Biden likely won’t win that age group, but it’s certainly grown in four years, so it is critical for him to hold on to as many of those voters as possible, especially in swing states ...
- Orchid Pharma gets USFDA nod, to market its new drug in US soonon February 23, 2024 at 3:43 am
Vertically integrated pharma player Orchid Pharma Ltd said on Friday that it will launch its Enmetazobactam drug in the US in the next couple of quarters.The company has received approval from the ...
- When AI Helps Generate Inventions, Who Is the Inventor?on February 22, 2024 at 1:41 pm
AI advancements will contribute more and more significantly to the invention processes, blurring the lines of inventive contribution and raising the question of whether AI should be considered a joint ...
via Bing News